HC Wainwright Analysts Raise Earnings Estimates for ACTU

Actuate Therapeutics, Inc. (NASDAQ:ACTU) – Stock analysts at HC Wainwright lifted their Q3 2026 earnings estimates for Actuate Therapeutics in a research report issued to clients and investors on Tuesday, August 18th. HC Wainwright analyst S. Ramakanth now anticipates that the company will earn ($0.15) per share for the quarter, up from their prior estimate of ($0.21). HC Wainwright currently has a “Buy” rating on the stock. The consensus estimate for Actuate Therapeutics’ current full-year earnings is ($0.86) per share. HC Wainwright also issued estimates for Actuate Therapeutics’ Q4 2026 earnings at ($0.15) EPS, FY2026 earnings at ($0.61) EPS, Q1 2027 earnings at ($0.13) EPS, Q2 2027 earnings at ($0.12) EPS, Q3 2027 earnings at ($0.13) EPS, Q4 2027 earnings at ($0.13) EPS, FY2027 earnings at ($0.51) EPS, FY2028 earnings at ($0.50) EPS, FY2029 earnings at $0.15 EPS and FY2030 earnings at $1.28 EPS.

Actuate Therapeutics (NASDAQ:ACTU) last issued its quarterly earnings results on Friday, August 14th. The company reported ($0.20) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.21) by $0.01.

Other research analysts have also issued reports about the company. Weiss Ratings restated a “sell (e+)” rating on shares of Actuate Therapeutics in a research note on Wednesday, June 24th. Rodman & Renshaw began coverage on shares of Actuate Therapeutics in a report on Thursday, July 30th. They issued a “buy” rating and a $6.00 price target on the stock. Finally, Wall Street Zen cut shares of Actuate Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 23rd. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Actuate Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $13.67.

Actuate Therapeutics Trading Up 1.0%

Shares of ACTU stock opened at $1.06 on Thursday. Actuate Therapeutics has a 12 month low of $0.90 and a 12 month high of $9.22. The company has a market capitalization of $25.45 million, a P/E ratio of -1.22 and a beta of 0.78. The stock has a 50 day moving average of $1.44 and a two-hundred day moving average of $2.38.

Hedge Funds Weigh In On Actuate Therapeutics

Several hedge funds have recently added to or reduced their stakes in the stock. Voss Capital LP increased its stake in Actuate Therapeutics by 45.0% in the fourth quarter. Voss Capital LP now owns 1,300,000 shares of the company’s stock valued at $7,956,000 after purchasing an additional 403,722 shares in the last quarter. Texas Capital Bank Wealth Management Services Inc acquired a new position in shares of Actuate Therapeutics in the 2nd quarter valued at $157,000. Palogic Value Management L.P. bought a new stake in shares of Actuate Therapeutics in the 2nd quarter valued at $153,000. BlackRock Inc. bought a new stake in shares of Actuate Therapeutics in the 2nd quarter valued at $138,000. Finally, Geode Capital Management LLC increased its position in shares of Actuate Therapeutics by 252.5% in the 2nd quarter. Geode Capital Management LLC now owns 118,050 shares of the company’s stock valued at $721,000 after buying an additional 84,561 shares in the last quarter.

Actuate Therapeutics News Summary

Here are the key news stories impacting Actuate Therapeutics this week:

• Positive Sentiment: HC Wainwright raised earnings estimates across multiple periods. The firm improved its forecasts for Q3 and Q4 2026 EPS to $(0.15), compared with previous estimates of $(0.21) and $(0.23), respectively. It also raised estimates for Q1–Q4 2027 to losses of $(0.13), $(0.12), $(0.13), and $(0.13) per share. HC Wainwright Reiterates Buy Rating for Actuate Therapeutics
• Positive Sentiment: The full-year outlook also improved materially. HC Wainwright raised its FY2026 EPS forecast to $(0.61) from $(0.84), FY2027 to $(0.51) from $(0.71), and FY2028 to $(0.50) from $(0.75). The firm now expects Actuate to become profitable in FY2029, forecasting $0.15 per share versus its prior estimate of a $(0.07) loss, and increased its FY2030 forecast to $1.28 from $1.24.
• Positive Sentiment: HC Wainwright maintained its Buy rating. The repeated endorsement provides a favorable signal, particularly because the firm’s revised estimates imply faster improvement in profitability than previously expected. HC Wainwright Reiterates Buy Rating on Actuate Therapeutics
• Neutral Sentiment: The revisions are analyst projections rather than new operating results. Actuate remains unprofitable, with a consensus forecast of $(0.86) EPS for the current fiscal year, so the investment case continues to depend on execution and eventual clinical or commercial progress.

About Actuate Therapeutics

Actuate Therapeutics (NASDAQ: ACTU) is a clinical-stage oncology company focused on the discovery and development of targeted therapies designed to address key drivers of tumor growth and survival. Headquartered in South San Francisco, California, the company applies a precision medicine approach to identify novel molecular targets and develop small-molecule agents that have the potential to improve outcomes for patients with difficult-to-treat cancers.

The company’s lead asset, atuveciclib, is a selective, oral CDK9 inhibitor being evaluated in a Phase 1 clinical trial for patients with acute myeloid leukemia and advanced solid tumors.